Sign in

    Tommy Han

    Research Analyst at Robert W. Baird & Co. Incorporated

    Tommy Han is an Equity Research Analyst at Robert W. Baird & Co. Incorporated specializing in the medical technology sector. He covers publicly traded medtech companies, leveraging his research background to deliver rigorous investment analysis, though specific performance track record and rankings are not publicly documented. Han began his career as a Client Advisor and Equity Analyst at Bessemer Trust, as well as serving as an Intellectual Property Protection Analyst with the Global Impact Investing Network, before joining Baird in 2023. He holds a Bachelor of Business Administration in Finance and Global Affairs from the University of Notre Dame and is FINRA registered as Thomas J Han, CRD# 7782607.

    Tommy Han's questions to InMode (INMD) leadership

    Tommy Han's questions to InMode (INMD) leadership • Q3 2024

    Question

    Tommy Han questioned the significant jump in U.S. system installations, asking if it included all preorders from the first half of the year. He also inquired if the sharp increase in Average Selling Price (ASP) was due to one-time factors or sustainable price hikes.

    Answer

    CEO Moshe Mizrahy and CFO Yair Malca confirmed that all preorders were delivered and recognized in Q3, accounting for the installation jump. Mizrahy attributed the higher ASP to premium pricing on the new Ignite and OptimasMAX platforms during their initial launch phase, but cautioned that maintaining this elevated ASP would be difficult and that prices on the existing portfolio cannot be raised.

    Ask Fintool Equity Research AI